Alembic Pharmaceuticals Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹2,149.77 crore, reflecting a quarter-on-quarter *(QoQ) increase of 16.35 per cent from ₹1,847.72 crore. This corresponds to a year-on-year *(YoY) growth of 25.66 per cent.
Operating Profit
Operating Profit stands at ₹331.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 63.35 per cent from ₹203.16 crore. This corresponds to a year-on-year *(YoY) growth of 18.14 per cent.
PBDT
PBDT stands at ₹319.57 crore, reflecting a quarter-on-quarter *(QoQ) increase of 54.23 per cent from ₹207.21 crore. This corresponds to a year-on-year *(YoY) growth of 21.10 per cent.
Profit Before Tax
Profit Before Tax stands at ₹221.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 87.03 per cent from ₹118.62 crore. This corresponds to a year-on-year *(YoY) growth of 16.70 per cent.
Net Profit
Net Profit stands at ₹172.36 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 14.47 per cent from ₹201.53 crore. This represents a 12.19 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Alembic Pharmaceuticals Ltd News
Alembic Pharmaceuticals Ltd Earnings
- YOY
- QOQ
Alembic Pharmaceuticals Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Alembic Pharmaceuticals Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Alembic Pharmaceuticals Ltd Financial Reports
Alembic Pharmaceuticals Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Alembic Pharma | 0.55% | -0.29% | 3.01% | 7.56% | 9.38% | -16.20% |
| OneSource Speci. | -0.16% | -1.12% | -7.19% | -15.18% | 15.96% | -18.55% |
| Alivus Life | -1.42% | -3.22% | 22.43% | 28.68% | 52.43% | 38.84% |
| Concord Biotech | -0.25% | 3.69% | 25.68% | 38.47% | 45.56% | -8.54% |
| Shilpa Medicare | -0.74% | 0.72% | 34.18% | 59.11% | 154.61% | 91.51% |
| Natco Pharma | 0.28% | -0.81% | -4.16% | -24.75% | -6.56% | 0.87% |
| Marksans Pharma | 0.53% | -3.14% | 30.46% | 45.86% | 84.52% | 80.68% |
Company Info
Company Information
Chairman and MD & CEO : Chirayu R Amin
Independent Director : Pranav N Parikh
Independent Director : K G Ramanathan
Independent Director : Paresh Saraiya
Director & CFO : Rajkumar Baheti
Independent Director : Milin Mehta
Managing Director : Pranav Amin
Managing Director : Shaunak Amin
Independent Director : Archana Hingorani
Company Secretary : Charandeep Singh Saluja